{
  "source": "PA-Med-Nec-Idiopathic-Pulmonary-Fibrosis-Esbriet-Ofev.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Name 2025 P 2046-14\nProgram Prior Authorization/Medical Necessity\nMedications Esbriet® (pirfenidone)* and Ofev® (nintedanib)\nP&T Approval Date 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 10/2019, 4/2020,\n4/2021, 4/2022, 3/2023, 3/2024, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nEsbriet (pirfenidone) is a pyridone and Ofev (nintedanib) is a kinase inhibitor that are indicated\nfor the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is also indicated for slowing the\nrate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial\nlung disease (SSc-ILD) and for the treatment of chronic fibrosing interstitial lung diseases\n(ILDs) with a progressive phenotype.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Idiopathic pulmonary fibrosis\n1. Initial Authorization\na. Esbriet* and Ofev will be approved based on all of the following criteria:\n(1) Diagnosis of idiopathic pulmonary fibrosis (IPF) as documented by all of the\nfollowing criteria:\n(a) Exclusion of other known causes of interstitial lung disease (e.g., domestic\nand occupational environmental exposures, connective tissue disease, and\ndrug toxicity), as documented by the following:\ni. ICD-10 Code J84.112 (Idiopathic pulmonary fibrosis)\n-AND-\n(b) One of the following:\ni. In patients not subjected to surgical lung biopsy, the presence of a usual\ninterstitial pneumonia (UIP) pattern on high-resolution computed\ntomography (HRCT) revealing IPF or probable IPF5\n-OR-\nii. In patients subjected to a lung biopsy, both HRCT and surgical lung\nbiopsy pattern reveal IPF or probable IPF5\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) One of the following:\n(a) If request is for Esbriet, Esbriet is not being used in combination with Ofev.\n(b) If request is for Ofev, Ofev is not being used in combination with Esbriet.\n-AND-\n(3) The prescriber is a pulmonologist.\nAuthorization w",
    "sbriet, Esbriet is not being used in combination with Ofev.\n(b) If request is for Ofev, Ofev is not being used in combination with Esbriet.\n-AND-\n(3) The prescriber is a pulmonologist.\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Esbriet will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Esbriet therapy.\n-AND-\n(2) Esbriet is not being used in combination with Ofev.\nb. Ofev will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Ofev therapy.\n-AND-\n(2) Ofev is not being used in combination with Esbriet.\nAuthorization will be issued for 12 months\nB. Systemic sclerosis-associated interstitial lung disease (Ofev only)\n1. Initial Authorization\na. Ofev will be approved based on all of the following criteria:\n(1) Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) as\ndocumented by all of the following criteria:11\n(a) One of the following:\ni. Skin thickening of the fingers of both hands extending proximal to the\nmetacarpophalangeal joints\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n2\nii. At least two of the following:\n• Skin thickening of the fingers (e.g., puffy fingers, sclerodactyly of\nthe fingers)\n• Fingertip lesions (e.g., digital tip ulcers, fingertip pitting scars)\n• Telangiectasia\n• Abnormal nailfold capillaries\n• Pulmonary arterial hypertension\n• Raynaud’s phenomenon\n• SSc-related autoantibodies (e.g., anticentromere, anti-topoisomerase\nI, anti-RNA polymerase III)\n-AND-\n(b) Presence of interstitial lung disease as determined by finding evidence of\npulmonary fibrosis on HRCT, involving at least 10% of the lungs\n-AND-\n(2) Ofev is not being used in combination with Esbriet.\n-AND-\n(3) The prescriber is a pulmonologist.\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Ofev will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Ofev therapy.\n-AND-\n(2",
    "Authorization will be issued for 12 months\n2. Reauthorization\na. Ofev will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Ofev therapy.\n-AND-\n(2) Ofev is not being used in combination with Esbriet.\nAuthorization will be issued for 12 months\nC. Chronic fibrosing interstitial lung disease with a progressive phenotype (Ofev only)\n1. Initial Authorization\na. Ofev will be approved based on all of the following criteria:\n(1) Diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive\nphenotype as documented by both of the following criteria:\n(a) Presence of fibrotic ILD as determined by finding evidence of pulmonary\n© 2025 UnitedHealthcare Services, Inc.\n3\nfibrosis on HRCT, involving at least 10% of the lungs\n-AND-\n(b) Patient is presenting with clinical signs of progression as defined by one of\nthe following in the previous 24 months:\ni. Forced vital capacity (FVC) decline of greater than 10%\n-OR-\nii. Two of the following:\n1. FVC decline of greater than or equal to 5%, but less than 10%\n2. Patient is experiencing worsening respiratory symptoms\n3. Patient is exhibiting increasing extent of fibrotic changes on chest\nimaging\n-AND-\n(2) Ofev is not being used in combination with Esbriet\n-AND-\n(3) The prescriber is a pulmonologist\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Ofev will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Ofev therapy\n-AND-\n(2) Ofev is not being used in combination with Esbriet\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Brand Esbriet is typically excluded from coverage. Tried/Failed criteria may be in place. Please\nrefer to plan specifics to determine exclusion status.\n© 2025 UnitedHealthcare Se",
    " programs may apply.\n*Brand Esbriet is typically excluded from coverage. Tried/Failed criteria may be in place. Please\nrefer to plan specifics to determine exclusion status.\n© 2025 UnitedHealthcare Services, Inc.\n4\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Esbriet [Prescribing Information]. Genentech USA, Inc. South San Francisco, CA. February\n2023.\n2. King TE, Bradford WZ, Castro-Benardini S, et al. A phase 3 trial of pirfenidone in patients\nwith idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.\n3. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary\nfibrosis (CAPACITY): two randomized trials. Lancet. 2011;377:1760-69.\n4. Ofev® [Prescribing Information]. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield,\nCT. October 2024.\n5. Richeldi L, du Boise RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic\npulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82.\n6. Richeldi L, Cottin V, Flaherty KR, et al. Design of the INPULSIS trials: two phase 3 trials of\nnintedanib in patients with idiopathic pulmonary fibrosis. Resp Med. 2014;108:1023-1030.\n7. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and\nProgressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical\nPractice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47.\ndoi:10.1164/rccm.202202-0399ST\nProgram Prior Authorization/Medical Necessity - Esbriet® (pirfenidone) and\nOfev® (nintedanib)\nChange Control\n11/2014 New Program\n11/2015 Annual Review. Updated background info. Administrative changes.\n9/2016 Annual Review. Removed ICD-9 codes. Updated background and\nref",
    " and\nOfev® (nintedanib)\nChange Control\n11/2014 New Program\n11/2015 Annual Review. Updated background info. Administrative changes.\n9/2016 Annual Review. Removed ICD-9 codes. Updated background and\nreferences.\n9/2017 Annual Review. Updated background and references.\n9/2018 Annual Review. No change in coverage criteria. Updated references.\n9/2019 Annual Review. No change in coverage criteria. Updated references.\n10/2019 Added coverage criteria for systemic sclerosis for Ofev. Updated\nreferences.\n4/2020 Updated background and added Ofev coverage criteria for chronic\nfibrosing interstitial lung diseases with a progressive phenotype.\nUpdated references.\n4/2021 Annual Review. No change in coverage criteria. Updated references.\n4/2022 Annual Review. No change in coverage criteria. Updated references.\n3/2023 Annual Review. Reformatted criteria for Esbriet and Ofev for\n© 2025 UnitedHealthcare Services, Inc.\n5\nIdiopathic Pulmonary Fibrosis. Added exclusion footnote for Brand\nEsbriet and updated references.\n3/2024 Annual review. No change in coverage criteria. Updated references.\n5/2024 Removed prescriber requirement from reauthorization criteria.\n5/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}